Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy
- PMID: 5935707
- DOI: 10.1016/0002-9378(66)90173-6
Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy
Abstract
PIP: To determine the long-range gynecological and histological effects of parenteral progesterone administration during pregnancy, 10 pregnant women, 15-25 years old, were given a total of 500 mg medroxyprogesterone acetate (Depo-Provera) in 100 mg weekly intramuscular injections from Weeks 30-36 of gestation, and compared to 10 other pregnant women as controls during pregnancy and up to 8 weeks postpartum. Prolonged dysfunctional uterine bleeding occurred in 6 out of 11 patients treated with Depo-Provera and did not occur in the controls. Endometrial biopsies at the time of delivery were similar for both groups, but 6-8 weeks postpartum the treated patients showed persistent inactivity. 24-hour urinary excretions of FSH, 17-KS, 17 OHCS, estradiol and estrone were similar for both groups throughout the study as were the Metoprione test for pituitary function and PBI determinations. Urinary excretions of pregnanediol, estriol and total estrogen were lower in the treated patients at the end of pregnancy and postpartum. Evaluation of a larger series of 77 pregnant patients treated with Depo-Provera led to the finding that the drug's effect on the menstrual cycle dissipated within 1 year. 32 of these patients subsequently became pregnant with 28 successful deliveries and 4 spontaneous abortions. Depo-Provera is concluded to cause prolonged ovarian suppression and suppressed placental synthesis of progesterone and estriol.
Similar articles
-
Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.Acta Obstet Gynecol Scand. 1977;56(1):43-8. doi: 10.3109/00016347709158338. Acta Obstet Gynecol Scand. 1977. PMID: 842303
-
Contraception with an injectable progestin. A study of its use in postpartum women.Am J Obstet Gynecol. 1968 Aug 15;101(8):1046-53. doi: 10.1016/0002-9378(68)90346-3. Am J Obstet Gynecol. 1968. PMID: 5663345
-
Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.Lancet. 1980 Mar 8;1(8167):509-12. doi: 10.1016/s0140-6736(80)92765-8. Lancet. 1980. PMID: 6102234
-
[Contraception with injectable long-acting preparation depo-provera].Akush Ginekol (Mosk). 1995;(3):7-10. Akush Ginekol (Mosk). 1995. PMID: 7653732 Review. Russian.
-
[Prolonged-action contraceptives].Akush Ginekol (Mosk). 1987 Sep;(9):7-8. Akush Ginekol (Mosk). 1987. PMID: 3322079 Review. Russian.
Cited by
-
Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.Cochrane Database Syst Rev. 2018 Dec 17;12(12):CD012203. doi: 10.1002/14651858.CD012203.pub2. Cochrane Database Syst Rev. 2018. PMID: 30556599 Free PMC article.
-
Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.Cochrane Database Syst Rev. 2017 Oct 31;10(10):CD012024. doi: 10.1002/14651858.CD012024.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 Nov 20;2019(11). doi: 10.1002/14651858.CD012024.pub3. PMID: 29086920 Free PMC article. Updated. Review.
-
Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth.Cochrane Database Syst Rev. 2013 Jul 31;2013(7):CD004947. doi: 10.1002/14651858.CD004947.pub3. Cochrane Database Syst Rev. 2013. PMID: 23903965 Free PMC article. Review.
-
Progestogen for treating threatened miscarriage.Cochrane Database Syst Rev. 2018 Aug 6;8(8):CD005943. doi: 10.1002/14651858.CD005943.pub5. Cochrane Database Syst Rev. 2018. PMID: 30081430 Free PMC article.
-
Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology.Cochrane Database Syst Rev. 2019 Nov 20;2019(11):CD003511. doi: 10.1002/14651858.CD003511.pub5. Cochrane Database Syst Rev. 2019. PMID: 31745982 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources